江苏诺泰澳赛诺生物制药股份有限公司监事会 特此公告。 江苏诺泰澳赛诺生物制药股份有限公司监事会 2025 年 6 月 26 日 1 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）监事会依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）和《江苏 诺泰澳赛诺生物制药股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，对公司 2023 年限制性股票激励计划（以下简称"本次激励计划"）第二个归 属期归属名单进行审核，发表核查意见如下： 除 3 名激励对象因离职丧失激励对象资格，不符合归属条件外，本次拟归属 的 62 名激励对象符合《公司法》《证券法》等法律、法规和规范性文件以及《公 司章程》规定的任职资格，符合《上市公司股权激励管理办法》《上海证券交易 所科创板股票上市规则》等法律、法规和规范性文件规定的激励对象条件，符合 本次激励计划规定的激励对象范围，其作为公司本次限制性股票激励计划激励对 象的主体资格合法、有效， ...

一、审议通过了《关于调整 2023 年限制性股票激励计划相关事项的议案》 证券代码：688076 证券简称：诺泰生物 公告编号：2025-050 江苏诺泰澳赛诺生物制药股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）第四届董事会 第二次会议于2025 年 6月 26 日下午15:30 在公司会议室以现场与通讯方式召开， 会议通知于 2025 年 6 月 20 日以电子邮件方式送达全体董事。本次会议应出席董 事 9 人，实际出席董事 9 人，会议由董事长童梓权先生主持。会议的召开程序符 合有关法律法规、规范性文件和《公司章程》的规定，会议合法、有效。 经全体与会董事审议，本次会议以投票表决方式审议通过了以下议案： 议案内容：详见《江苏诺泰澳赛诺生物制药股份有限公司关于调整 2023 年 限制性股票激励计划相关事项的公告》（公告编号：2025-052）。本议案已经薪酬 与考核委员会审议通过。 表决结果：同意 7 票，反对 0 票， ...

Group 1 - The stock of Nuotai Bio (688076) has a comprehensive score of 47.97, indicating a weak performance [1] - The main cost analysis shows the following prices: current main cost at 37.83 CNY, 5-day main cost at 37.45 CNY, 20-day main cost at 37.40 CNY, and 60-day main cost at 36.77 CNY [1][3] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - The stock has seen a net inflow of 46.99 million CNY on June 20, 2025, accounting for 8% of the total trading volume [2] - The stock's short-term resistance is at 39.00 CNY and support at 35.79 CNY, while the mid-term resistance is at 40.42 CNY and support at 33.76 CNY [2] - The K-line pattern indicates a "Lotus Flower" formation, suggesting a rebound from the bottom [2][3] Group 3 - Financial data shows earnings per share at 0.69 CNY, operating profit at 178 million CNY, and net profit at approximately 147.87 million CNY [4] - The sales gross margin stands at 70.204% [4] - The stock is associated with various sectors, including medical services (-0.67%), CRO (-0.12%), influenza (-0.16%), and hepatitis concept (+0.35%) [4]

Group 1 - The financing balance of the Sci-Tech Innovation Board increased by 1.234 billion yuan compared to the previous day, with 55 stocks seeing an increase of over 10 million yuan in financing balance [1] - As of June 10, the total margin balance of the Sci-Tech Innovation Board reached 154.686 billion yuan, an increase of 1.235 billion yuan from the previous trading day [1] - Among the stocks on the Sci-Tech Innovation Board, 399 had a financing balance exceeding 100 million yuan, with 18 stocks having a balance over 1 billion yuan [1] Group 2 - The stock with the highest net financing purchase was Haiguang Information, with a latest financing balance of 3.763 billion yuan, increasing by 628.779 million yuan, and the stock rose by 4.30% on that day [2] - Other notable stocks with significant net purchases included Zhongwei Company and Nuotai Biological, with net purchases of 64.465 million yuan and 55.095 million yuan respectively [2] - The average decline for stocks with net purchases exceeding 10 million yuan was 1.29%, while stocks with the highest gains included Huicheng Co., Junshi Biological, and Xinyu Ren, with increases of 12.53%, 9.24%, and 5.18% respectively [2] Group 3 - The average financing balance as a percentage of market capitalization for stocks with significant net purchases was 3.61%, with the highest ratio being 8.00% for Maixinlin [2] - Other stocks with high financing balance ratios included Zhongke Lanyun at 7.76%, Yuntian Lifi at 6.98%, and Maiwei Biological at 6.59% [2] - The sectors attracting financing interest included electronics, pharmaceuticals, and computers, with 20, 12, and 8 stocks respectively [2]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Group 1 - The stock of Nuotai Bio (688076) has a comprehensive score of 56.66, indicating a strong performance [1] - The main cost analysis shows the current price at 56.69 yuan, with a 5-day cost of 52.44 yuan, a 20-day cost of 53.45 yuan, and a 60-day cost of 52.16 yuan [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - The short-term resistance level is at 55.18 yuan, while the short-term support level is at 48.86 yuan [2] - The stock has broken through the short-term resistance level, suggesting potential short-term strength, and also the mid-term resistance level, indicating possible mid-term strength [2] - The K-line pattern shows a "Red Three Soldiers" formation, indicating a potential bottoming out and recovery [2] Group 3 - On June 10, 2025, the net inflow of main funds was 57.82 million yuan, accounting for 7% of the total transaction amount [2] - The net inflow from large orders was 29.53 million yuan, while the net inflow from super large orders was 28.29 million yuan [2] - Retail investors contributed a net inflow of 41.05 thousand yuan [2] Group 4 - The latest financial data shows earnings per share at 0.69 yuan, operating profit at 178 million yuan, and net profit at approximately 147.87 million yuan [2] - The sales gross margin stands at 70.204% [2] - The stock is associated with sectors such as medical services (0.15%), CRO (1.13%), influenza (0.35%), and hepatitis concepts (0.98%) [2]

Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

Policy Developments - The National Health Commission is promoting the implementation of the "Blood Fee Waiver, No Need to Run Once" policy, aiming for full compliance by the end of 2025 across all blood stations and medical institutions in the country [1] Drug and Device Approvals - LuKang Pharmaceutical announced that its subsidiary has received approval for the consistency evaluation of Cimetidine Injection, which is used to treat symptoms caused by excessive stomach acid [2] - Baiyunshan reported that its subsidiary has received a drug registration certificate for Tadalafil Tablets, which are primarily used to treat erectile dysfunction [3] - Fuyuan Pharmaceutical announced that its subsidiary has received a drug registration certificate for Bromhexine Hydrochloride Oral Solution, suitable for treating respiratory diseases related to mucus secretion or clearance [4] Capital Market Activities - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor [5] - NuoTai Bio and NuoWeiZan signed a strategic cooperation agreement for a synthetic biology project, planning to establish a joint biopharmaceutical company [6] Industry Events - A medical team in the UK is experimenting with processing healthy human feces into freeze-dried powder to help patients infected with superbugs, showing promising results [8] - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, aiming to provide assessments and consultations for patients [9] - Kelong Pharmaceutical responded to accusations regarding its Ergotamine Capsules, clarifying that the product is classified as a dietary supplement rather than a drug [10] - Green Valley Pharmaceutical has halted production of the controversial drug Mannitol Sodium Capsules due to expired registration and ongoing scrutiny of its clinical trials [11] - Weili Zhibo Biotechnology has received approval from the China Securities Regulatory Commission for its IPO and the full circulation of its unlisted shares [12][14]

Core Viewpoint - The strategic cooperation between Nuotai Bio and Nuowei Zhan aims to establish a joint biopharmaceutical company focused on synthetic biology technology, enhancing both companies' capabilities in the field [1][2][3] Group 1: Partnership Details - Nuotai Bio will hold a 51% stake in the joint venture, while Nuowei Zhan will hold 49%, with respective contributions of 45.90% and 44.10% [1] - The partnership will be implemented in two phases, with the first phase focusing on the renovation of existing capacities and the application for DMF of raw materials [1] - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [1] Group 2: Company Strengths - Nuotai Bio is a leading company in the peptide drug sector, having overcome production bottlenecks and achieved industry-leading production levels of over 10 kilograms per batch for drugs like Semaglutide and Aibowei [2] - Nuowei Zhan specializes in the development of functional proteins and high molecular organic materials, holding a leading position in the field of in vitro diagnostic reagents [2] Group 3: Strategic Implications - The collaboration is expected to leverage the strengths of both companies in synthetic biology and peptide drugs, driving product and technology upgrades [3] - The strategic partnership aims to establish an advanced synthetic biology technology platform, promoting interdisciplinary collaboration and industry upgrades [3]

截至2025年6月6日收盘，诺泰生物（688076）报收于50.17元，较上周的48.06元上涨4.39%。本周，诺 泰生物6月4日盘中最高价报51.48元。6月3日盘中最低价报47.76元。诺泰生物当前最新总市值112.82亿 元，在化学制药板块市值排名41/150，在两市A股市值排名1402/5148。 公司公告汇总 诺泰生物发布了2024年年度权益分派实施公告，主要内容如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 每股派发现金红利0.80元，每股转增0.40股。 以方案实施前的公司总股本224,870,915股为基数，共计派发现金红利179,896,732.00元，转增 89,948,366股，本次分配后总股本为314,819,281股。 股权登记日为2025年6月11日，除权（息）日、新增无限售条件流通股份上市日和现金红利发放日 均为2025年6月12日。 利润分配及转增股本方案经公司2025年5月23日的2024年年度股东大会审议通过。 对于不同类型的股东，现金红利所得税政策有所不同： 持有公司无限售条件流通股的 ...